Dr. Reddy's Laboratories
About: Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Employees: 27,811
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,777% more call options, than puts
Call options by funds: $244K | Put options by funds: $13K
3% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 33
1.07% less ownership
Funds ownership: 14.19% [Q4 2024] → 13.12% (-1.07%) [Q1 2025]
2% less funds holding
Funds holding: 244 [Q4 2024] → 239 (-5) [Q1 2025]
22% less capital invested
Capital invested by funds: $1.87B [Q4 2024] → $1.45B (-$415M) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 113
67% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 1 (-2) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HSBC Damayanti Kerai | 7%upside $16.90 | Buy Upgraded | 5 Jun 2025 |
Financial journalist opinion
Based on 3 articles about RDY published over the past 30 days
